Schwab Charles Investment Management Inc. lifted its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 63.9% in the third quarter, HoldingsChannel.com reports. The firm owned 60,716 shares of the specialty pharmaceutical company’s stock after buying an additional 23,663 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Eagle Pharmaceuticals were worth $3,622,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its holdings in shares of Eagle Pharmaceuticals by 58.7% in the second quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock valued at $194,000 after purchasing an additional 908 shares during the period. Kopp Investment Advisors LLC grew its holdings in shares of Eagle Pharmaceuticals by 0.3% in the second quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 10 shares during the period. Municipal Employees Retirement System of Michigan grew its holdings in shares of Eagle Pharmaceuticals by 68.1% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,300 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $276,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $292,000.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) opened at $62.09 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The firm has a market cap of $926.51, a PE ratio of 9.79 and a beta of 1.24. Eagle Pharmaceuticals, Inc. has a 12 month low of $45.05 and a 12 month high of $97.15.

A number of equities research analysts recently issued reports on EGRX shares. Piper Jaffray Companies reissued a “buy” rating and issued a $75.00 price objective on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. ValuEngine raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $75.00 price objective (down previously from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $62.33.

ILLEGAL ACTIVITY NOTICE: “Schwab Charles Investment Management Inc. Has $3.62 Million Position in Eagle Pharmaceuticals, Inc. (EGRX)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-3-62-million-position-in-eagle-pharmaceuticals-inc-egrx/1806776.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.